ASTX660
Modify Date: 2025-08-27 10:39:02
ASTX660 structure
|
Common Name | ASTX660 | ||
|---|---|---|---|---|
| CAS Number | 1799328-86-1 | Molecular Weight | 539.68 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H42FN5O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ASTX660ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP). |
| Name | ASTX660 |
|---|
| Description | ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP). |
|---|---|
| Related Catalog | |
| Target |
cIAP, XIAP[1] |
| In Vitro | ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660[1]. |
| In Vivo | In HCC1806 xenografts in mice, ASTX660 (daily oral treatment) causes moderate tumor growth inhibition but not regression[1]. |
| References |
| Molecular Formula | C30H42FN5O3 |
|---|---|
| Molecular Weight | 539.68 |
| Storage condition | 2-8℃ |